Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Centessa Pharmaceuticals (CNTA) Total Current Liabilities (2022 - 2025)

Centessa Pharmaceuticals (CNTA) has disclosed Total Current Liabilities for 4 consecutive years, with $42.9 million as the latest value for Q4 2025.

  • Quarterly Total Current Liabilities fell 25.97% to $42.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $42.9 million through Dec 2025, down 25.97% year-over-year, with the annual reading at $42.9 million for FY2025, 25.97% down from the prior year.
  • Total Current Liabilities for Q4 2025 was $42.9 million at Centessa Pharmaceuticals, up from $29.1 million in the prior quarter.
  • The five-year high for Total Current Liabilities was $58.0 million in Q4 2024, with the low at $24.2 million in Q1 2025.
  • Average Total Current Liabilities over 4 years is $33.7 million, with a median of $31.6 million recorded in 2022.
  • The sharpest move saw Total Current Liabilities surged 47.26% in 2024, then decreased 25.97% in 2025.
  • Over 4 years, Total Current Liabilities stood at $38.3 million in 2022, then grew by 2.73% to $39.4 million in 2023, then soared by 47.26% to $58.0 million in 2024, then decreased by 25.97% to $42.9 million in 2025.
  • According to Business Quant data, Total Current Liabilities over the past three periods came in at $42.9 million, $29.1 million, and $29.7 million for Q4 2025, Q3 2025, and Q2 2025 respectively.